MARKET

RLYB

RLYB

Rallybio Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.90
+0.32
+2.36%
After Hours: 13.90 0 0.00% 16:00 09/24 EDT
OPEN
13.51
PREV CLOSE
13.58
HIGH
14.29
LOW
12.92
VOLUME
39.59K
TURNOVER
--
52 WEEK HIGH
25.78
52 WEEK LOW
10.05
MARKET CAP
446.61M
P/E (TTM)
-1.3976
1D
5D
1M
3M
1Y
5Y
BRIEF-Rallybio Corp Posts Q2 Loss Per Share $2.80
reuters.com · 09/09 11:42
Rallybio Reports Wider Q2 Loss as Operating Expenses Rise
MT Newswires · 09/09 08:04
GSAT, ATER and PXLW among mid-day movers
Gainers: Kadmon (NASDAQ:KDMN) +73%. ICU Medical (NASDAQ:ICUI) +32%. Candel Therapeutics (NASDAQ:CADL) +23%. Globalstar (NYSE:GSAT) +22%. Spectrum Brands (NYSE:SPB) +20%. Vinco Ventures (NASDAQ:BBIG) +19%. WISeKey (NASDAQ:WKEY) +14%. SilverBow (NYSE:SBOW) +...
Seekingalpha · 09/08 17:29
Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2021
Upgrades JP Morgan upgraded the previous rating for Pearson PLC (NYSE:PSO) from Neutral to Overweight. The current stock performance of Pearson shows a 52-week-high of $12.38 and a 52-week-low of $6.13. Moreover, at the end of the last trading period, the...
Benzinga · 08/23 14:20
Evercore ISI Group Initiates Coverage On Rallybio with Outperform Rating, Announces Price Target of $40
Evercore ISI Group analyst Josh Schimmer initiates coverage on Rallybio (NASDAQ:RLYB) with a Outperform rating and announces Price Target of $40.
Benzinga · 08/23 12:40
Cowen & Co. Initiates Coverage On Rallybio with Outperform Rating
Cowen & Co. analyst Ritu Baral initiates coverage on Rallybio (NASDAQ:RLYB) with a Outperform rating.
Benzinga · 08/23 11:53
Jefferies Initiates Coverage On Rallybio with Buy Rating, Announces Price Target of $20
Jefferies analyst Eun Yang initiates coverage on Rallybio (NASDAQ:RLYB) with a Buy rating and announces Price Target of $20.
Benzinga · 08/23 11:52
--Jefferies Starts Rallybio at Buy With $20 Price Target
MT Newswires · 08/23 07:25
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RLYB. Analyze the recent business situations of Rallybio Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RLYB stock price target is 30.00 with a high estimate of 40.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 32.13M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Key Executives
Director
Lucian Iancovici
Chief Medical Officer
Steven Ryder
Director
Kush M. Parmar
Director
Paula Soteropoulos
Director
Helen M. Boudreau
Director
Rob Hopfner, R.Ph.
Chief Executive Officer and Chairman
Martin W. Mackay
President, Chief Operating Officer and Chief Scientific Officer
Stephen Uden
Director
Ronald M. Hunt
Chief Financial Officer and Treasurer
Jeffrey M. Fryer
Director
Timothy M. Shannon
No Data
About RLYB
Rallybio Corporation is a clinical-stage biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering therapies that improve the lives of patients suffering from severe and rare diseases. It offers program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare hematological disease that impacts fetuses and newborns. It provides RLYB211, a polyclonal anti-HPA-1a antibody. Its RLYB211 is in a Phase I/II clinical trial. It focuses on developing therapies that address diseases of dysregulation, including paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), and ophthalmic disorders. RLYB116 is a novel, administered inhibitor of complement factor 5 (C5), in development for the treatment of patients with PNH and gMG. It develops RLYB114, which is a pegylated C5 inhibitor in preclinical development for the treatment of complement-mediated ophthalmic diseases.

Webull offers kinds of Rallybio Corp stock information, including NASDAQ:RLYB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLYB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RLYB stock methods without spending real money on the virtual paper trading platform.